Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
LongeVC is a venture capital firm located in Washington D.C., established to invest in biotechnology and longevity-focused startups. The firm supports early-stage founders aiming to develop breakthrough solutions that can significantly impact human healthspan and lifespan. LongeVC is recognized for its commitment to advancing the longevity industry through strategic investments in innovative biotech solutions.
Currently, LongeVC manages a portfolio of 25 companies, focusing on pre-seed, seed, seed-plus, and Series A funding stages. The firm emphasizes personalized medicine, advanced diagnostics, and foundational platform technologies. LongeVC has built a reputation for its expertise in navigating the complexities of drug development and market entry, making it a valuable partner for startups in the biotech sector.
Notable milestones include the establishment of a diverse portfolio that showcases the firm’s dedication to fostering innovation in biotechnology. LongeVC's office in Washington D.C. serves as a hub for collaboration and growth within the longevity sector, connecting founders with essential resources and industry insights.
LongeVC invests primarily in early-stage companies that are pioneering innovative solutions in biotechnology, particularly in the fields of personalized medicine, advanced diagnostics, and foundational platform technologies. Their investment strategy encompasses pre-clinical and clinical stage drug development companies that investigate the molecular and cellular mechanisms of aging. This focus aligns with their overarching goal of supporting advancements in human healthspan and lifespan.
The firm typically engages with startups at the pre-seed, seed, seed-plus, and Series A stages, providing check sizes that facilitate initial growth and development. LongeVC seeks to partner with founders who demonstrate a strong vision for their companies and a commitment to addressing significant challenges in healthcare. Their investment thesis emphasizes integrated healthcare solutions that expedite drug discovery and testing processes, ensuring that portfolio companies can effectively bring their innovations to market.
LongeVC's portfolio consists of 25 companies, each contributing to the advancement of biotechnology and longevity. Notable companies include:
Garri Zmudze: Managing Partner with extensive experience in venture capital and biotechnology.
Ilya Suharenko: Managing Partner, specializing in early-stage investments in biotech.
Sergey Jakimov: Managing Partner with a focus on longevity and healthspan investments.
Vlad Cernoutan: Senior Associate with expertise in biotech startups.
Artem Trotsyuk: Operating Partner - US, providing operational support to portfolio companies.
Tom Sturitis: Chief Operational Officer, overseeing firm operations.
Konstantinos Maitos: Chief Financial Officer, managing financial strategies.
Artemy Shumskiy: Senior Associate, focusing on investment analysis.
Pascal Schümperli: Partner with a background in biotech investments.
James Bogenberger: Therapeutics Team Lead, specializing in drug development.
Greg Fishman: Venture Partner with experience in health technology.
Matthew Toner: Venture Partner focused on early-stage biotech.
Aurora Griffin: Venture Partner with expertise in longevity.
Timothy Morris: Venture Partner with a background in healthcare investments.
Evelyne Bischof: Venture Partner specializing in biotech.
Evgeny Izumchenko: Venture Partner with a focus on drug discovery.
Luis Angel: Venture Partner with experience in health technology.
Matt Kaeberlein: Venture Partner specializing in aging research.
Michael Levitt: Venture Partner with a background in biotechnology.
Mike Martin: Venture Partner focused on early-stage investments.
Miro Venturi: Venture Partner with expertise in biotech.
Vadim Gladyshev: Venture Partner specializing in aging research.
Tzipi Strauss: Venture Partner with a focus on healthspan.
Alex Zhavoronkov: Venture Partner with expertise in AI and biotech.
Nir Barzilai: Advisory Board Member, known for his work in aging research.
Thomas Rando: Advisory Board Member with expertise in regenerative medicine.
Yousin Suh: Head of Advisory Board, guiding strategic initiatives.
Christine Yuan Huang: Advisory Board Member with a focus on biotech.
John Mikhael: Advisory Board Member with experience in venture capital.
Maja Magdalena Kaczmarek: Venture Fellow with a focus on biotech.
Dr. Weigao Wang: Venture Fellow specializing in aging research.
Jiahao Liang: Venture Fellow with expertise in biotechnology.
Yifei Wang: Venture Fellow focused on health technology.
Pengwei Sun: Venture Fellow with a background in biotech.
Jiexuan Jiang: 2023 Class Fellow specializing in biotech.
Gege Qian: 2023 Class Fellow with a focus on longevity.
Ryan L. Keivanfar: 2023 Class Fellow with expertise in healthspan.
Yuanjin Zhang: 2025 Class Fellow specializing in biotech.
Naftali Horwitz: 2025 Class Fellow with a focus on aging research.
Laiba Jamshed Khan: 2024 Class Fellow specializing in health technology.
To pitch LongeVC, founders should use the preferred channel of their website or email their pitch deck to hq@longevc.com. The pitch deck should include a concise overview of the business model, market opportunity, team background, and any preliminary data or traction. Founders can expect a response within a few weeks, depending on the volume of submissions. Warm introductions are beneficial but not mandatory.
What are LongeVC's investment criteria?
LongeVC focuses on early-stage companies in biotechnology and longevity, particularly those developing personalized medicine, advanced diagnostics, and foundational platform technologies. They invest in pre-clinical and clinical stage drug development companies that explore the mechanisms of aging.
How can I apply or pitch to LongeVC?
Founders can pitch their ideas through the firm's website at longevc.com or by emailing their pitch deck to hq@longevc.com. It is advisable to include a clear overview of the business model, market opportunity, and team background.
What makes LongeVC different from other venture capital firms?
LongeVC specializes in biotechnology and longevity, making it one of the few firms dedicated to this sector. Their deep expertise in drug development and market entry provides significant value to portfolio companies.
What is LongeVC's geographic scope?
The firm primarily invests in companies based in the United States, focusing on startups that align with their investment thesis in biotechnology and longevity.
What type of post-investment involvement does LongeVC have?
LongeVC actively supports its portfolio companies by providing strategic guidance, industry connections, and resources to help navigate the complexities of drug development and market entry.
What is the typical fund size and check size for LongeVC?
While specific fund sizes are not disclosed, LongeVC invests in early-stage rounds, typically providing check sizes that align with pre-seed, seed, seed-plus, and Series A funding stages.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.